Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Janux Therapeutics Inc’s stock clocked out at $23.96, down -2.00% from its previous closing price of $24.45. In other words, the price has decreased by -$2.00 from its previous closing price. On the day, 0.86 million shares were traded. JANX stock price reached its highest trading level at $24.34 during the session, while it also had its lowest trading level at $23.52.
Ratios:
To gain a deeper understanding of JANX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 58.47 and its Current Ratio is at 58.47. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 03, 2024, Reiterated its Buy rating but revised its target price to $70 from $63 previously.
On December 03, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $82 to $100.
On November 22, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $79.Leerink Partners initiated its Outperform rating on November 22, 2024, with a $79 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 01 ’25 when Meyer Andrew Hollman sold 3,333 shares for $32.03 per share. The transaction valued at 106,745 led to the insider holds 82,139 shares of the business.
ANDREW MEYER bought 3,333 shares of JANX for $110,656 on May 01 ’25. On Apr 21 ’25, another insider, Meyer Andrew Hollman, who serves as the Chief Business Officer of the company, sold 3,334 shares for $30.00 each. As a result, the insider received 100,020 and left with 82,139 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1417837696 and an Enterprise Value of 375412128. For the stock, the TTM Price-to-Sale (P/S) ratio is 151.80 while its Price-to-Book (P/B) ratio in mrq is 1.40. Its current Enterprise Value per Revenue stands at 40.211 whereas that against EBITDA is -3.366.
Stock Price History:
The Beta on a monthly basis for JANX is 2.86, which has changed by -0.424868 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $22.48. The 50-Day Moving Average of the stock is -6.66%, while the 200-Day Moving Average is calculated to be -39.03%.
Shares Statistics:
It appears that JANX traded 966.28K shares on average per day over the past three months and 742730 shares per day over the past ten days. A total of 59.17M shares are outstanding, with a floating share count of 49.54M. Insiders hold about 16.29% of the company’s shares, while institutions hold 110.17% stake in the company. Shares short for JANX as of 1749772800 were 10610234 with a Short Ratio of 10.98, compared to 1747267200 on 11548285. Therefore, it implies a Short% of Shares Outstanding of 10610234 and a Short% of Float of 25.94.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
